<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579978</url>
  </required_header>
  <id_info>
    <org_study_id>TIME</org_study_id>
    <nct_id>NCT04579978</nct_id>
  </id_info>
  <brief_title>Tumor Immunotherapy and Microbiome Analysis</brief_title>
  <acronym>TIME</acronym>
  <official_title>Tumor Immunotherapy and Microbiome Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The composition of the gut microbiome has been associated with response and the development&#xD;
      of toxicities on immune checkpoint inhibitors (ICIs) in multiple tumor types. The aim of this&#xD;
      study is to examine the gut microbiome composition in patients undergoing standard of care&#xD;
      treatment for advanced/unresectable and/or metastatic solid tumors with ICIs. Fecal samples&#xD;
      and peripheral blood samples will be collected to further characterize the diversity of gut&#xD;
      bacteria and to study potential mechanisms by which gut bacteria impact the immune response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study of gut microbial markers. Patients with histologically confirmed&#xD;
      advanced/unresectable or metastatic solid tumors who are planned to initiate standard of care&#xD;
      ICIs or are undergoing standard of care treatment with ICIs will be approached for&#xD;
      participation in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative abundance and composition of immunotherapy response-associated bacterial species in patients with advanced/unresectable or metastatic solid tumors</measure>
    <time_frame>6 months</time_frame>
    <description>Fecal microbial composition analyzed by 16S rRNA and metagenomic sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative abundance and composition of immunotherapy toxicity-associated bacterial species in patients with advanced/unresectable or metastatic solid tumors</measure>
    <time_frame>12 months</time_frame>
    <description>Fecal microbial composition analyzed by 16S rRNA and metagenomic sequencing; IgA sequencing of fecal samples from patients who develop diarrhea/colitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the composition of the intestinal microbiome induced by ICIs</measure>
    <time_frame>6 months</time_frame>
    <description>Fecal microbial composition analyzed by 16S rRNA and metagenomic sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of bacterial DNA in peripheral blood samples</measure>
    <time_frame>6 months</time_frame>
    <description>Blood microbial abundance measured via qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in immune cell subsets in the systemic circulation upon progression on ICIs correlated with changes in microbiome composition</measure>
    <time_frame>2 years</time_frame>
    <description>Flow cytometry of blood at baseline and at development of progressive disease and analysis of microbiome composition at baseline and at development of progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of serum metabolites in systemic circulation and correlation with intestinal microbiome composition</measure>
    <time_frame>6 months</time_frame>
    <description>Analysis of serum metabolites using chromatography coupled to tandem mass spectrometry</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Subjects with advanced solid tumors starting immunotherapy</arm_group_label>
    <description>Subjects with advanced solid tumors planned to initiate standard of care immune checkpoint inhibitors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with advanced solid tumors receiving ICIs</arm_group_label>
    <description>Subjects with advanced solid tumors already receiving standard of care immune checkpoint inhibitors</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal samples will be collected for analysis of gut bacteria. Peripheral blood samples will&#xD;
      be collected via phlebotomy for analysis of immune markers and circulating bacteria.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with advanced/unresectable or metastatic solid tumors either planned to&#xD;
        start standard of care treatment with ICIs or already on treatment with ICIs.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign written and voluntary informed consent&#xD;
&#xD;
          -  Adult patients aged &gt;=18, male or female&#xD;
&#xD;
          -  Eastern Cooperative Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Histologic diagnosis of an advanced/unresectable or metastatic solid tumor&#xD;
&#xD;
          -  Measurable disease as per RECIST 1.1 criteria&#xD;
&#xD;
          -  Be suitable for or receiving ICI treatment&#xD;
&#xD;
          -  Prior immunotherapy allowed&#xD;
&#xD;
          -  Be willing and able to provide fecal and blood specimens for analysis as per protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of inflammatory bowel disease, chronic diarrhea or&#xD;
             malabsorption syndromes and significant prior bowel resection as judged by the study&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rossanna C. Pezo, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rossanna C. Pezo, MD/PhD</last_name>
    <phone>416-480-4757</phone>
    <email>rossanna.pezo@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossanna C. Pezo, MD/PhD</last_name>
      <phone>416-480-4757</phone>
      <email>rossanna.pezo@sunnybrook.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune Checkpoint Inhibitor</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Immune-Mediated Toxicity</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

